LSD1 Inhibitors via Local Quality and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current LSD1 and LSD2 inhibitors lack selectivity and potency, making them inadequate for effectively interacting with crucial amino acid residues in the substrate-binding site, thereby limiting their therapeutic potential in cancer treatment and other diseases associated with LSD dysfunction.
Innovation Solution
Development of compounds that selectively inhibit LSD1 or LSD2 by binding to the FAD domain, disrupting interactions with proteins like HDAC1/2, CoREST, and other complexes, and exhibiting subtype selectivity, thereby modulating LSD activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current LSD1 and LSD2 inhibitors are used, then some inhibition activity is achieved, but selectivity and potency are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at particular positions on the molecular core structure. These localized modifications at specific sites (positions 1-6 on the benzene ring and substituent positions) enable selective interaction with crucial amino acid residues in the substrate-binding site, achieving both high selectivity and potency without requiring complete structural redesign
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halo, hydroxyl, cyano, amino, alkyl, alkoxy groups) and their positions on the molecular scaffold. This approach allows optimization of binding affinity and selectivity parameters while maintaining the core inhibitory mechanism, resolving the contradiction between achieving high reliability and managing structural complexity
2Reliability
If inhibitors bind to FAD domain to disrupt protein interactions, then therapeutic potential is improved, but selectivity between LSD1 and LSD2 is challenging
Solution Approach 1:
The patent applies segmentation by dividing the molecular inhibitor into distinct functional segments: a core structure that binds to the FAD domain and subtype-specific substituent groups (R1-R6) that provide selectivity. This segmented approach allows the inhibitor to simultaneously engage the conserved FAD binding site while discriminating between LSD1 and LSD2 through specific substituent-protein interactions
Solution Approach 2:
The patent uses the FAD domain as an intermediary target. By designing inhibitors that bind to the FAD domain (which is conserved between LSD1 and LSD2) while incorporating subtype-selective substituents, the molecule mediates selective inhibition. The FAD domain serves as the primary binding interface, while the substituent groups act as secondary recognition elements that provide subtype discrimination
Data Source
AI summary
In one aspect, the invention relates to substituted (E)-N'-(1- phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.